We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Thérapeutiques ciblées uni- ou multicibles?
- Authors
Duffaud, F.; Salas, S.
- Abstract
Clinical experience with targeted therapies is at an early stage, but an increasing number of treatment options is likely to become available in the near future. This paper explores our current understanding of molecular-targeted therapies and considers the following: What approach should we use (single-targeted vs multi-targeted agents)? How should they be used (monotherapy or combination therapy)? And how do you overcome secondary resistance? In addition, we present two examples of multi-targeted therapy used after resistance to selective therapy in cases of GIST resistance to imatinib and, in breast cancer, resistance to trastuzumab, respectively.
- Subjects
BREAST cancer; CANCER research; MEDICAL research; IMMUNOSUPPRESSIVE agents; PHOSPHOTRANSFERASES; THERAPEUTICS
- Publication
Oncologie (Tech Science Press), 2006, Vol 8, Issue 9, p828
- ISSN
1292-3818
- Publication type
Article
- DOI
10.1007/s10269-006-0514-z